Strong facts, held-back story: management reports concrete strengthening but deliberately keeps expectations below it
The model's full reasoning — Q1 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否同时(1)报告了已经发生的实际业务改善(如订单、销量、客户、活动、胜利、利用率或产出增加),并且(2)明显抑制了这种优势——故意将陈述的预期或框架保持在比报告事实所支持的更保守的水平。 首先,检查是否有实际改善的报告。在电话会议中,管理层提到了CUDC-907的临床进展:他们完成了第一阶段单药治疗组的入组,25名患者中有8名出现客观缓解(之前报告为7/16,现在为8/19可评估患者)。他们还提到,回顾性分析显示临床获益可能与MYC癌基因抑制相关,并据此设计了第二阶段试验。此外,CA170即将进入临床,预计成为首个口服检查点抑制剂。这些是正在发生的进展,但并非典型的商业指标(如订单、销量等),而是临床试验进展。然而,这些是实际发生的改善:缓解率提高,试验推进。 其次,检查管理层是否抑制了这种优势。在电话会议中,管理层对CUDC-907的回应率表示“非常健康”,但并未大幅提高预期。他们提到,与FDA讨论过阈值,但尚未给出具体数字。对于CA170,他们表示预期本季度进入临床,但未给出具体数据时间。他们强调需要更多数据。此外,对于Erivedge,他们提到合作伙伴启动了新研究,但未提及自身预期。 关键点:管理层是否在报告实际改善的同时,故意保持预期保守?在电话会议中,管理层没有明确说“我们看到了强劲增长,但我们保持保守”,而是描述了进展,但并未大幅上调预期。例如,对于CUDC-907,他们提到“我们期望这种患者富集能提高第二阶段试验成功的可能性”,但并未给出具体预期。对于CA170,他们只是说“预期进入临床”,没有给出时间表或预期数据。 然而,问题要求的是“报告已经发生的、实际的优势”,并且“明显抑制这种优势”。这里,优势是临床进展,但并非商业上的订单或销量。但问题说“whatever form fits the business”,所以临床试验进展可以视为业务优势。管理层确实报告了实际改善(缓解率提高,试验推进),但他们的陈述是否比事实更保守?他们提到“我们非常满意”但并未夸大。他们也没有明确说“我们保持保守”,但他们的语气是谨慎的,例如“我们预期患者富集能提高成功率”,这暗示他们相信数据,但并未给出具体预期。 此外,他们提到“我们将在获得更多数据后与FDA讨论”,这表明他们不急于宣称成功。这可以视为一种抑制。 但问题要求“both halves come through in management's own words as one coherent posture”。管理层是否明确表示他们故意保持预期低于事实?在电话会议中,没有直接说“我们故意保守”,但他们的措辞可能暗示。例如,对于CUDC-907,他们提到“我们相信这个回应率是健康的”,但并未说“我们预期更高”。对于CA170,他们只是说“预期进入临床”,没有说“我们预期快速成功”。 然而,问题也指出,如果保守只是标准风险语言,则不算。这里,管理层的谨慎似乎与具体进展相关,例如他们强调需要更多数据,而不是仅仅说“有风险”。 但另一方面,管理层是否在报告实际改善的同时,明显抑制?他们报告了8/19的缓解率,但并未说“这比预期好”,而是说“我们相信这是健康的”。他们也没有提高全年指引(因为公司没有给出指引)。他们提到“我们期望患者富集能提高成功率”,这暗示他们相信数据,但并未给出具体数字。 我认为,管理层确实报告了实际改善(缓解率提高,试验推进),并且他们的陈述相对保守,没有夸大。但这是否构成“明显抑制”?他们并没有说“我们看到了强劲势头,但我们保持保守”,而是以事实陈述方式描述进展。然而,他们的语气是谨慎的,例如“我们将在获得更多数据后与FDA讨论”,这暗示他们不急于宣称成功。 但问题要求“deliberately keeping stated expectations, forecasts, or framing more modest than the reported facts would support”。管理层没有给出明确的预期或预测,所以很难说他们是否保持更保守。他们只是描述进展,没有给出预期。因此,可能没有明显的差距。 此外,对于CA170,他们只是说“预期进入临床”,没有给出时间表或预期数据,这可能是正常的。 我认为,在这个电话会议中,管理层报告了实际进展,但并没有明显抑制优势。他们只是陈述事实,没有夸大,但也没有明确说“我们保持保守”。因此,可能不符合“明显抑制”的标准。 但让我们再仔细看:他们提到“我们期望这种患者富集能提高第二阶段试验成功的可能性”,这暗示他们相信数据,但并未给出具体预期。他们也没有说“我们预期高缓解率”。他们只是说“我们相信这是健康的”。 此外,对于CA170,他们提到“我们预期它成为世界首个口服检查点抑制剂”,这有点宣传性,但并非抑制。 总体而言,我认为管理层报告了实际改善,但他们的陈述并没有明显低于事实。他们只是谨慎地描述,没有夸大,但也没有故意压低预期。因此,可能不符合“明显抑制”的条件。 但问题要求“both halves come through”,所以如果只有一半,则回答NO。 我倾向于回答NO,因为虽然报告了实际改善,但抑制部分不明显。 然而,让我们再考虑:管理层提到“我们将在获得更多数据后与FDA讨论”,这可以视为一种抑制,因为他们没有立即宣称成功。但这是标准做法。 另外,他们提到“我们期望患者富集能提高成功率”,这暗示他们相信数据,但并未给出具体预期。 我认为,没有明显的“抑制”行为。因此,答案应为NO。 但为了确认,检查是否有任何地方管理层明确说“我们保持保守”或类似。没有。 因此,回答NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| PBR | Petróleo Brasileiro S.A. - Petrobras | Q4 2023 | 2024-03-08 | D |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| AEP | American Electric Power Company, Inc. | Q3 2023 | 2023-11-02 | C+ |
| PNNT | PennantPark Investment Corporation | Q3 2023 | 2023-08-10 | B+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| THS | TreeHouse Foods, Inc. | Q1 2023 | 2023-05-08 | B+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| ICL | ICL Group Ltd | Q3 2022 | 2022-11-09 | B+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CIVB | Civista Bancshares, Inc. | Q2 2022 | 2022-07-31 | B |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| PRGS | Progress Software Corporation | Q2 2022 | 2022-06-28 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| WMB | The Williams Companies, Inc. | Q3 2021 | 2021-11-02 | B |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| CPRX | Catalyst Pharmaceuticals, Inc. | Q2 2021 | 2021-08-10 | C+ |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| TSLX | Sixth Street Specialty Lending, Inc. | Q4 2017 | 2018-02-22 | C+ |
| LII | Lennox International Inc. | Q4 2017 | 2018-02-06 | B+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| AAT | American Assets Trust, Inc. | Q4 2016 | 2017-02-15 | C+ |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| BMO | Bank of Montreal | Q4 2016 | 2016-12-06 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| WAT | Waters Corporation | Q3 2016 | 2016-10-25 | C |
| BOH | Bank of Hawaii Corporation | Q3 2016 | 2016-10-24 | A |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| INGR | Ingredion Incorporated | Q1 2016 | 2016-05-01 | B+ |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
| ACCO | ACCO Brands Corporation | Q1 2016 | 2016-04-27 | B+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| JHX | James Hardie Industries plc | Q3 2016 | 2016-02-19 | B+ |
GTES · Q4 2021 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete, already-occurring strength in the business—rising orders, record backlog, book-to-build above 1, strong January order rates, specific design wins, and demand exceeding supply—while deliberately holding the story back by framing 2022 expectations as measured, pragmatic, and cautious, noting ongoing challenges through Q1 and not fully embedding the current momentum into the guidance range. This posture appears in their own words as they describe the facts running ahead of the outlook they are willing to share. The restraint is not mere boilerplate but a visible choice to under-promise relative to the reported strength.
BCOV · Q1 2018 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete strength in Q1 2018: revenue $41.2M exceeded high end of guidance, adjusted EBITDA positive $900k well above high end, recurring dollar retention 103% (multi-year high), strong bookings across businesses/geographies, notable wins including large auto company deal, Europe best 3+ years, completed commodity pricing reset, and digital marketing/enterprise activity showing productivity gains. They visibly hold the story back: full-year revenue guidance $165-168M (roughly flat vs. Q1 run-rate implying ~$164.8M), Q2 revenue guidance $41.
PII · Q3 2017 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND hold the story back from that strength? YES The transcript shows clear evidence of both elements in management's posture. They report concrete, already-occurring strength in the recent period—Q3 sales up 25% (adjusted), North American retail up 13% with RZR and NDN ahead, September as Polaris' highest retail month ever, August among top three 2017 months, off-road vehicles and Polaris retail up versus 2015 (not an easy comp), dealer inventory down 7%, and strong international/PG&A growth—while explicitly raising 2017 guidance (sales 18-19%, ORV/Snow mid-single digits, EPS $4.